Redefining
Regenerative
Medicine

Histogen is a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body. This innovative technology utilizes human proteins and growth factors produced by hypoxia-induced multipotent cells to address what Histogen believes to be underserved, multibillion dollar global markets.

ABOUT

clinical programs

Histogen is advancing three clinical programs in therapeutic indications with large commercial market opportunities:

HAIR GROWTH

Hair Growth

A minimally-invasive treatment that is intended to grow new hair, not simply preserve existing hair.

 
SKIN CARE

Dermal Fillers

Human-derived collagen and extracellular matrix dermal fillers delivering potentially longer-lasting effects with fewer side effects for the treatment of facial folds and wrinkles.

 
MATRIX REGENERATION

Joint Cartilage Repair

Histogen’s extracellular matrix for articular cartilage defects regenerates hyaline cartilage for the treatment of knee osteoarthritis with a novel malleable scaffold produced by the body’s own stem cells.

 

Latest News

September 16, 2020
Histogen Announces $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage Regeneration in the Knee

Investigational New Drug (IND) Filing Expected in the Fourth Quarter of 2020 SAN DIEGO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural

Read more
September 10, 2020
Histogen Announces Completion of Dosing Milestone in its 1b/2a Trial for Androgenic Alopecia in Men

Top Line Results Remain on Track for Q4’2020 SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO),  a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain

Read more
September 1, 2020
Histogen to Present at the HC Wainwright 22nd Annual Global Investment Conference

SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that

Read more
View All